Understand the source comparison
5-Amino-1MQ Peptide vs GLP-1 Agonists: Mechanism Comparison
Primary Mechanism NNMT inhibition → increased NAD+ → SIRT1 activation → fat oxidation GLP-1 receptor agonism → slowed gastric emptying + appetite suppression 5-amino-1mq targets cellular metabolism directly; GLP-1 works through satiety signaling Appetite Effec
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- NNMT inhibition → increased NAD+ → SIRT1 activation → fat oxidation
- GLP-1 receptor agonism → slowed gastric emptying + appetite suppression
- 5-amino-1mq targets cellular metabolism directly; GLP-1 works through satiety signaling
- Appetite Effect
- No direct appetite suppression
- 30–50% reduction in caloric intake via central and peripheral satiety pathways
- GLP-1 agonists require dietary compliance; 5-amino-1mq does not depend on eating less
- Weight Loss Mechanism
- Increased cellular fat oxidation at baseline metabolic rate
- Reduced caloric intake + improved insulin sensitivity
- 5-amino-1mq shifts how cells burn energy; GLP-1 shifts how much you eat
- NAD+ Involvement
- Directly increases NAD+ availability by blocking its depletion
- No direct NAD+ modulation
- NAD+ restoration is unique to NNMT inhibition—critical for mitochondrial function
- Side Effect Profile
- Minimal reported GI effects; no nausea or vomiting in preclinical models
- Nausea (30–45%), vomiting, diarrhea during titration phase
- 5-amino-1mq avoids the GI side effects that cause 15–20% discontinuation rates with GLP-1s
- Clinical Evidence Status
- Preclinical (animal models + in vitro); no human RCTs published as of 2026
- Multiple Phase III trials; FDA-approved formulations (Wegovy, Ozempic, Mounjaro)
- GLP-1 agonists have robust clinical validation; 5-amino-1mq remains investigational